Carl Zeiss Meditec Reports Revenue and Earnings Growth for 2024/25

Carl Zeiss Meditec AG announced a significant increase in revenue and earnings for the first nine months of fiscal year 2024/25. The company generated revenue of €1,600.1 million, marking a 7.6% increase compared to the previous year. The growth was mainly attributed to the consolidation of DORC and robust order intake, which rose by 23.3%.

In the Ophthalmology segment, revenue grew by 9.5%, driven by organic growth and the DORC acquisition. Meanwhile, the Microsurgery unit saw a 1.6% rise. Regionally, EMEA and Americas showed positive revenue contributions with increases of 11.7% and 14.2% respectively, while APAC achieved a modest 1.8% growth.

Despite challenges like negative currency effects and US trade tariffs, Carl Zeiss Meditec's EBITA increased to €175.4 million, although the EBITA margin slightly dipped to 11.0%. The company maintains an optimistic outlook for the fiscal year, expecting stable or slightly higher EBITA margins while addressing the impact of trade tariffs through pricing strategies.